Neuronetics_logo-RGB purple.png
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 27, 2024 16:30 ET | Neuronetics
MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics_logo-RGB purple.png
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
March 25, 2024 08:30 ET | Neuronetics
MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics_logo-RGB purple.png
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
March 07, 2024 08:22 ET | Neuronetics
MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics_logo-RGB purple.png
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
March 05, 2024 07:30 ET | Neuronetics
MALVERN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of...
Neuronetics_logo-RGB purple.png
Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call
February 20, 2024 08:30 ET | Neuronetics
MALVERN, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics_logo-RGB purple.png
Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
February 12, 2024 08:32 ET | Neuronetics
MALVERN, Pa., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics_logo-RGB purple.png
NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
February 06, 2024 08:28 ET | Neuronetics
MALVERN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics_logo-RGB purple.png
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results
January 08, 2024 08:30 ET | Neuronetics
MALVERN, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of...
Neuronetics_logo-RGB purple.png
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
December 18, 2023 08:49 ET | Neuronetics
MALVERN, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics_logo-RGB purple.png
NeuroStar TMS Receives Expanded Regulatory Approval in Japan
December 04, 2023 08:56 ET | Neuronetics
MALVERN, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...